Epocrates vs Lexicomp (UpToDate Lexidrug): cost, depth and which to buy

Yes. Wolters Kluwer rebranded Lexicomp as UpToDate Lexidrug, and the vendor store and university library guides now list it as "UpToDate Lexidrug (formerly Lexicomp)". It is one product line under two names, which is why a search for one turns up documentation written about the other. Confusingly, the mobile app still sells subscription packages under the older Lexicomp naming, so you can be looking at the new brand and the old package names on the same screen.

The practical consequence is that comparisons written before the rename are still about the current product, and you should not discount them as out of date on the name alone. It also means that when a colleague says their hospital "has Lexicomp", they almost certainly have Lexidrug access under a current Wolters Kluwer contract. If you are evaluating vendors, ask about Lexidrug; if you are searching for guidance, search both.

For an individual, the clearest published figure is the mobile subscription: Apple's US App Store listing for UpToDate Lexidrug shows in-app subscriptions (Lexicomp Professional Package and Lexi-COMPLETE) at $29.99, and the listing states that the subscription renews at $29.99 per month after the trial. Held for a year that is roughly $360, which is about double what Epocrates+ costs at $179.99 annually. We keep the current figures and the sourcing behind them in our breakdown of what Lexicomp and UpToDate Lexidrug actually cost.

For an organization there is no published list price at all. Lexidrug is sold to hospitals, health systems and libraries on negotiated contracts, and what you pay depends on headcount, which content sets you take and what else you already buy from the same vendor. You will see monthly dollar figures for Lexicomp quoted on software directory sites; those are not published by Wolters Kluwer and we do not repeat them, for the same reason we refuse to quote a list price for Micromedex. Ask for the quote, and ask for it next to the bundled configuration.

They are built for different depths of question. Epocrates is optimized for the thirty seconds you have in a corridor: open, search, get the dose or the interaction, close. Lexidrug is optimized for the question behind the question, the one where you need to know how a recommendation was derived, what the dosing looks like in an edge case, and what a pharmacist would flag. If you push Epocrates into that second job it runs out of detail, and if you push Lexidrug into the first it feels slow.

For most ambulatory prescribers who are paying personally, Epocrates wins on cost and speed and the free tier is genuinely usable. For pharmacists, hospitalists and anyone whose orders get verified by a pharmacy team, Lexidrug is the reference that matches the standard they will be held to. The honest answer for a lot of clinicians is that they use the free Epocrates tier daily and reach for their employer's Lexidrug license when the question gets hard. If you are weighing this against a broader evidence reference rather than another drug database, our UpToDate vs Epocrates comparison covers that trade-off.

It can, and in many health systems it does. Wolters Kluwer sells Lexidrug with integrations into major electronic health records including Epic, MEDITECH and Cerner, so clinicians reach drug content from context-specific links inside the chart rather than opening a separate app. In July 2026 Wolters Kluwer and Epic announced a combined offering that packages UpToDate Lexidrug with Medi-Span and patient education into a single integrated procurement, aimed particularly at rural hospitals, federally qualified health centers and smaller ambulatory practices that do not have the informatics staff to validate three standalone tools.

What that means for you is simple: whether you have it is a licensing question, not a product question. Before you pay for a personal subscription, log into your EHR and look for a drug reference link in the medication activity, and check your medical library, because a large number of US clinicians buy access their employer already provides. That single check saves more money than any comparison of list prices.

Both tools answer the question you think to ask. Neither one watches the prescription you are about to sign and tells you, unprompted, that this patient is already on something that interacts with it, that their kidney function makes the standard dose wrong, or that a documented allergy rules out the obvious first choice. Getting that from a drug reference means knowing to run four separate lookups, and prescribing errors cluster precisely where nobody thought to look.

That is the job Prescriber.io is built for. You enter the drug or the scenario once and it checks for drug-drug interactions, flags contraindications and allergy blockers, surfaces renal and hepatic dose adjustments, and suggests guideline-based alternatives, together, with a cited source on each flag so you can confirm it. It is decision-support, not autonomous prescribing: every flag is a prompt for a licensed clinician who reviews it, verifies against official sources, and signs. Clinicians who arrived here from a search for a Lexicomp alternative are usually after exactly this, a faster path from drug detail to a decision, and the wider field is laid out in our guide to the best clinical decision support software.